PCK2

Across TCGA pan-cancer cohorts, PCK2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of PCK2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where PCK2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PCK2 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

BLCA, KIRC, and KIRP are the cancer types where PCK2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCK2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	IV	+1.617	<.001	11	view →
KIRC	Male	All	−1.309	<.001	9	view →
KIRP	All	II,III,IV	−1.869	<.001	8	view →
LIHC	Female	All	−1.493	<.001	8	view →
HNSC	Male	All	+0.777	<.001	7	view →
UCEC	All	II,III,IV	+1.748	<.001	6	view →
BRCA	All	III,IV	+0.837	<.001	6	view →
LUAD	Female	All	−0.388	<.001	6	view →
CHOL	Male	All	−3.948	<.001	5	view →
COAD	Female	II,III,IV	−0.798	<.001	5	view →
KICH	All	All	−1.456	<.001	4	view →
PRAD	All	All	−0.224	.041	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

PCK2–BLCA

Open the BLCA breakdown →